Skip to content

Continuous Negative Abdominal Pressure in ARDS (CNAP in ARDS)

Continuous Negative Abdominal Pressure in ARDS (CNAP in ARDS)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03425318
Acronym
CNAP in ARDS
Enrollment
40
Registered
2018-02-07
Start date
2019-01-04
Completion date
2024-12-31
Last updated
2023-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Respiratory Distress Syndrome

Brief summary

The aim is to test a device for applying continuous negative abdominal pressure in patients with ARDS

Detailed description

Adult respiratory distress syndrome (ARDS) is a serious pulmonary disease affecting adults and children. It has a high mortality and there is no specific therapy. The mortality is high (approx. 40% in severe cases) and this has not changed in the last 20 years. Mechanical ventilation is the mainstay of management, and this assists the patient by increasing oxygenation and removal of carbon dioxide. Despite optimizing tidal volume, driving pressure and positive end-expiratory pressure (PEEP), patients with ARDS develop large areas of atelectasis and poor oxygenation. There are few additional ventilator approaches that have proven to be useful in preventing this type of injury. A major aim of ventilator support is recruitment of atelectatic (i.e. de-airated) lung, but while this is supported by excellent rational and laboratory data, the conventional clinical approaches have not been associated with a demonstrable improvement in patient outcome. Most atelectasis in ARDS occurs in the dorsal (dependant, lower-most) lung regions, and these are near the diaphragm. The main ways to recruit lung are to increase the airway distending pressure (but this over-expands and damages the already-aerated lung regions); or, to turn the patient into the prone position (but clinicians are reluctant to utilize this approach - despite evidence that it may increase survival). Continuous Negative Abdominal Pressure (CNAP) aims to selectively recruit basal atelectatic areas of lung, while enabling the patient to remain in the supine (usual) position.

Interventions

DEVICECNAP

Application of CNAP in patients with ARDS

Sponsors

Unity Health Toronto
CollaboratorOTHER
The Hospital for Sick Children
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. Patients ≧ 18 years old 2. Patients with moderate to severe ARDS as per the Berlin definition (PaO2/FiO2 ≤200mmHg) 3. Patients with absence of any significant cardiopulmonary disease

Exclusion criteria

1. Contraindication to CNAP a. open abdominal wounds or drainage tubes; b. Acute brain Injury with intracranial pressure \>30 mm Hg or cerebral perfusion pressure \<60 mmHg; c. Decompensated heart insufficiency or acute coronary syndrome; d. Major hemodynamic instability: Mean arterial pressure lower than 60 mm Hg despite adequate fluid resuscitation and two vasopressors or increase of vasopressor dose by 30% in the next 6 hours; f. Unstable spine, femur, or pelvic fractures; g. Pregnancy; h. Pneumothorax; 2. Contraindication to EIT electrode placement: Burns, chest wall bandaging limiting electrode placement 3. Severe liver insufficiency (Child-Pugh score \> 7) or fulminant hepatic failure 4. Major respiratory acidosis or PaCO2 \> 60 mmHg 5. Severe COPD (according to the GOLD criteria defined as severe = FEV1: 30-50% or very severe = FEV1 \< 30%) 6. Clinical judgement of the attending physician

Design outcomes

Primary

MeasureTime frameDescription
Hypotension (SAFETY)30 minReduction in mean arterial pressure to less than 60 mmHg or by 15%
Oxygen Saturation (SAFETY30 minReduction in oxygen saturation (SpO2) by 5% or more
Oxygenation (SAFETY)30 minReduction in P-to-F ratio (PaO2/FiO2) by \>20%

Secondary

MeasureTime frameDescription
Oxygenation (EFFICACY)30 minIncrease in PaO2/FiO2 by \>20%

Countries

Canada

Contacts

Primary ContactDoreen Engelberts
doreen.engelberts@sickkids.ca416 813 8891
Backup ContactLaurent Brochard, MD
Laurent.Brochard@unityhealth.to416 864 5686

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026